Aspirin associated with lower risk of liver cancer

A Swedish nationwide registry-based study has examined the risk of hepatocellular carcinoma (HCC) and liver-related mortality associated with low-dose aspirin use in patients infected with hepatitis B or hepatitis C viruses. A total of 50,275 patients who received a diagnosis of chronic hepatitis B or hepatitis C between 2005 and 2015 were identified, 14,205 of whom were established as low-dose aspirin users according to prescription data. On the basis of a median 7.9 years follow-up, the estimated cumulative incidence of HCC was shown to be significantly lower among aspirin users than nonusers (4.0% versus 8.3%; P < 0.001), an association that was also found to be dependent on the duration of aspirin use. The 10-year liver-related mortality was also significantly lower among aspirin users than nonusers (11.0% versus 17.9%; P <0.001), but importantly, there was no significant difference in the 10-year risk of gastrointestinal bleeding between the groups.


Original article

  1. Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018–1028 (2020)

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Iain Dickson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. Aspirin associated with lower risk of liver cancer. Nat Rev Gastroenterol Hepatol 17, 260 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing